Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug pricing, AIDS and the developing nations

    Project Inform Perspective
    |August 13, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Access to HIV treatment in developing nations requires innovative solutions beyond the expensive Western model. Current healthcare spending is insufficient to provide care for all individuals living with HIV/AIDS.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010

    Area of Science:

    • Global Health
    • Infectious Diseases
    • Public Health Policy

    Background:

    • The escalating global burden of Acquired Immunodeficiency Syndrome (AIDS) necessitates urgent attention, particularly in Africa and other developing regions.
    • Current treatment paradigms for Human Immunodeficiency Virus (HIV) in North America and Europe, costing $10,000-$20,000 annually per patient, are unsustainable for low-income countries with minimal healthcare budgets.
    • The disparity in healthcare expenditure highlights a critical gap in access to life-saving antiretroviral therapies and support services for millions affected by HIV/AIDS worldwide.

    Discussion:

    • The economic infeasibility of the established Western model for HIV/AIDS treatment in resource-limited settings is a primary concern.
    • A paradigm shift is required, moving away from 'business as usual' to explore cost-effective and scalable interventions.
    • Addressing the AIDS epidemic in developing nations demands innovative strategies tailored to local economic realities and healthcare infrastructures.

    Related Experiment Videos

    Key Insights:

    • The current North American and European HIV treatment model is economically prohibitive for developing nations.
    • Significant disparities exist in healthcare spending, impacting access to essential HIV/AIDS care.
    • Urgent need for alternative, affordable treatment and support strategies for HIV-infected individuals globally.

    Outlook:

    • Future research and policy should focus on developing low-cost antiretroviral drugs and sustainable healthcare delivery systems.
    • International collaboration is crucial to bridge the treatment gap and improve health outcomes for people with HIV/AIDS in resource-limited settings.
    • Exploring innovative financing mechanisms and public-private partnerships can enhance access to HIV/AIDS treatment and reduce mortality rates.